Patients
Neuropsychiatric Disorders:
A widespread and growing challenge
Neuropsychiatric disorders represent a wide range of debilitating conditions, affecting an individual’s cognition, emotional regulation, or behaviour. Anxiety disorders, depression (MDD), bipolar disorder, schizophrenia and post-traumatic stress disorder (PTSD) are among the most common. According to the World Health Organization (WHO), approximately 1 in every 8 people globally is affected by a neuropsychiatric disorder. For a significant proportion of these individuals, their condition is poorly managed with available treatments, highlighting the pressing need for better treatments.
Patient Resources:
- US: National Alliance on Mental Illness (NAMI) https://www.nami.org/
- US: Depression and Bipolar Support Alliance (DBSA) https://www.dbsalliance.org/
- Europe: European Alliance Against Depression (EAAD) https://www.eaad.net/
- UK: NHS Mental Health Conditions https://www.nhs.uk/mental-health/conditions/depression-in-adults/overview/
About Major Depressive Disorder
Major Depressive Disorder (MDD) is one of the most common neuropsychiatric disorders and a leading cause of global disease burden. In the US and Europe alone, more than 30 million individuals are diagnosed with and treated for MDD.
MDD is characterized by persistent feelings of sadness, loss of interest in daily activities, poor concentration and low energy levels. These symptoms often interfere with work, relationships, and overall well-being and are associated with increased morbidity and mortality.
While many pharmacological treatment options are available, their efficacy is often limited and side effect profiles are significant, impacting patients’ compliance and resulting in suboptimal clinical outcomes. While existing therapies help some people, over 50% do not achieve sufficient symptom relief with first-line antidepressant medication and approximately one-third of those receiving antidepressant treatment are classified as treatment resistant.
Therefore, there is a pressing need for new antidepressants that overcome the limitations of existing treatments and enable people with depression to live their best life.